Intuitive Surgical, Inc.

Intuitive Surgical’s 2025 10-K presents a business model where the initial sale is not for the faint of heart, or the impatient. The MD&A details a sales process for major capital equipment purchase that typically involves a “lengthy sales cycle,” a phrase that often implies significant customer commitment and a measured pace of new account acquisition. Domestic revenue consistently formed the bulk of operations, accounting for 68% in 2025, with international markets contributing the remaining 32%. This geographical distribution has remained stable, with domestic revenue ranging from 66% to 68% over the past three years.

The forensic scores paint a picture of financial stability. Beneish’s 1999 eight-ratio earnings-manipulation detector registered -2.5138, a value comfortably below the -1.78 threshold, suggesting lower risk of earnings manipulation. Altman’s Z″ — a 1968 bankruptcy-distress index — stood at 44.56, placing the company well within the “safe” zone, far exceeding the 2.60 benchmark. While Piotroski’s F-Score, a 9-point fundamental strength scan, and the Fog Index, a readability score, are not available for this filing, the existing metrics offer a clear signal regarding the company’s financial health.

The MD&A further elaborates on the company’s sales structure, distinguishing between a capital sales team focused on selling systems and a clinical sales team responsible for supporting those systems in procedures. This division underscores the strategic importance of both initial placements and ongoing utilization within hospital accounts, including integrated delivery network (“IDN groups”). The characterization of initial system sales as a “major capital equipment purchase” highlights the substantial investment required from customers, implying a business model built on long-term relationships rather than rapid transactional volume.

This filing provides a clear view into Intuitive Surgical’s revenue geography and its methodical sales approach for complex medical devices. It highlights the stable distribution of domestic versus OUS revenue and the strategic segmentation of its sales force. However, without specific financial figures beyond percentages, or the benefit of risk factor excerpts, the filing does not offer a complete quantitative assessment of operational risks or growth drivers. A comprehensive view of the security’s valuation would require additional financial data and an understanding of the broader market for medical instruments.